At Miracle Inside Diagnostic Scan Clinic in Leeds, we offer access to OncoNext® Risk genetic testing, a blood-based hereditary cancer risk test designed to identify inherited gene changes that may increase a person’s lifetime risk of developing certain cancers.
This test looks for germline mutations — inherited genetic changes present in all cells of the body, which may be passed down through families.
OncoNext® Risk is suitable for people who want to understand better their inherited cancer risk, especially where there is a family history of early-onset cancer, multiple cancers in the same family, or known hereditary cancer syndromes.
1 in 2 People Will Develop Cancer in Their Lifetime
Half of the UK population born after 1960 will be diagnosed with cancer during their lifetime. Alarmingly, nearly 50% are diagnosed after the cancer has already spread. Understanding your genome allows you to make proactive lifestyle and environmental changes to reduce your risk of developing cancers you may be genetically predisposed to.
Genes play a critical role in disease occurrence, and understanding your genome takes proactive healthcare to the next level. Most people carry inherited genetic mutations that increase their risk for certain cancers and diseases. While we cannot change our DNA, we can change our environment and lifestyle.
By knowing your genetic predisposition, OncoNext® empowers you to make informed decisions to reduce your cancer risk, through targeted lifestyle modifications and preventive care.
Hereditary cancers often involve germline mutations – inherited changes in a gene that may increase cancer risk.
With OncoNext®, you can take control of your health, making proactive choices to reduce the likelihood of developing genetically predisposed cancers.
OncoNext® Risk is a genetic test that analyses selected cancer-related genes using advanced molecular testing.
The test focuses on genes involved in:
Changes in these genes may increase susceptibility to specific types of cancer.
This is not a test to diagnose active cancer. It is designed to assess whether you carry inherited genetic variants that may increase your future risk.
OncoNext® Risk testing is available for targeted cancer areas, including:
Includes genes such as:
ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, PALB2, RAD51C, RAD51D, STK11, TP53, PTEN
Includes genes such as:
APC, BMPR1A, CDH1, EPCAM, GREM1, MLH1, MSH2, MSH6, MUTYH, PMS2, POLD1, PTEN, SMAD4, STK11, TP53
Includes genes such as:
BRCA1, BRCA2, BRIP1, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, CHEK2, ATM
Includes genes such as:
ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53
Includes genes such as:
ATM, BRCA1, BRCA2, CHEK2, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, TP53
A focused test for inherited mutations in:
BRCA1 and BRCA2
These genes are strongly associated with hereditary breast and ovarian cancer risk.
The complete OncoNext® Risk panel screens approximately 80–82 genes associated with hereditary cancer predisposition.
Take Control of Your Health: Understand Your Risks and Reduce Them. OncoNext analyses your genetic makeup to identify gene mutations that may increase your cancer risk. Many of these mutations are inherited and can be influenced by environmental factors and lifestyle choices. By understanding your genome, you can make informed adjustments to lower your cancer risk and take charge of your health for a healthier future..
ATM, BARD, BRCA1, BRCA2, BRIP1 CDH1, CHEK2, MRETIA, MUTYH, NBN, NF, PALB2, PTEN, RADSO, RADSIC, RADSID, STK11, TP53
BRCA1, BRCA2, BRIP1, EPCAM, MLH1,MSH2, MSH6, PALB2, PMS2, PTEN, RADS1C, RADS1D, STK11, TP53
APC, BMPR1A, CDH1, CHEK2, EPCAM, GREM1, MLH1, MSH2, MSH6, MUTYH, PMS2, POLD1, PTEN, SMAD4, STK11, TP53
APC, BMPR1A, CDH1, EPCAM, MLHT, MSH2, MSH6, PMS2, STKT1, SMAD4, TPS3
APC, ATM, BMPR1A, BRCA1, BRCA2, CDKN2A, ERPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STKI1, TP53
BAP1, BRCA2, CDK4, CDKN2A, MITF, PTEN, RB1, TP53
ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51D, TPS3
AIP, ALK, APC, CDKN1B, CDKN2A, DICER1, MEN1, MLH1, MSH2, MSH6, NBN, NF1, NF2, PHOX2B, PMS2, PRKARIA, PTCH1, PTEN, SMARCA4, SMARCBIT, SMARCE1, SUFU, TP53, TSCI, TSC2, VHL
BAP1, EPCAM, FH, FLCN, MET, MITF, MLH1, MSH2, MSH6, PMS2, PTEN, SDHA, SDHB, SDHC, SDHD, TP53,TSC1,TSC2,VHL
FH, MAX, MEN1, NF1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEMI27, VHL
This test may be suitable if you:
A positive result means a hereditary gene mutation has been detected.
This does not mean you currently have cancer, and it does not mean you will definitely develop cancer.
It may mean you have a higher inherited risk compared with the general population. This can help guide:
A negative result means no reportable mutation was found in the genes tested.
However, this does not completely remove cancer risk. Cancer can still occur due to non-inherited factors, lifestyle, environment, ageing or gene changes not covered by the test.
At Miracle Inside in Leeds, we provide a professional and supportive pathway for private genetic testing.
We can help with:
To discuss hereditary cancer risk testing or to book an appointment, contact Miracle Inside Diagnostic Scan Clinic.
Call: 01134408760
Website: www.miracleinside.com
Location: Leeds, West Yorkshire
No. OncoNext® Risk is not designed to diagnose active cancer. It checks for inherited genetic mutations that may increase lifetime cancer risk.
Yes. The test requires a blood sample, usually collected in an EDTA tube.
Approximately 10 mL of blood is usually required.
Results usually take around 15–30 working days from when the laboratory receives the sample.
Yes. Germline DNA does not usually change over time, so hereditary cancer risk testing is generally a one-time test.
No. A positive result means you may have an increased inherited risk, but it does not mean cancer is certain.
No. A negative result does not remove all cancer risk. It only means no reportable mutation was found in the genes tested.
Panels are available for breast, ovarian, uterine, colon, gastric, pancreatic, prostate, melanoma, renal, cerebral tumours, thyroid-related risk and other hereditary cancer groups.
BRCA1 and BRCA2 testing is available either as a focused BRCA panel or as part of wider hereditary cancer panels.
Yes. Genetic testing can have implications for you and your relatives, so pre- and post-test counselling or healthcare professional discussion is strongly recommended.
We offer a wide range of blood tests, but the list below is not comprehensive. If you can’t find what you need or need more information, please feel free to contact us at 01138301371 and speak to one of our healthcare professionals. We’ll be more than happy to help you out.